Adjunctive Therapy with Curcumin for Peptic Ulcer: A Randomized Controlled Trial

A. Khonche, O. Biglarian, Y. Panahi, G. Valizadegan, S.S. Soflaei, M.E. Ghamarchehreh, M. Majeed, Amirhossein Sahebkar

    Research output: Contribution to journalArticlepeer-review

    36 Citations (Scopus)


    © Georg Thieme Verlag KG Stuttgart, New York.Background: Curcumin, the bioactive ingredient of turmeric, has been shown to improve the treatment of peptic ulcer (PU) in animal studies. However, clinical studies confirming this effect of curcumin have been scant. Objective: To assess the efficacy of adjunctive therapy with curcumin on the eradication of Helicobacter pylori infection and severity of dyspepsia in patients with PU. Methods: In this randomized double-blind placebo-controlled parallel-group trial, patients diagnosed with PU were assigned to standard H. pylori eradication triple therapy with clarithromycin (500 mg b.i.d.), amoxicillin (1 000 mg b.i.d.) and pantoprazole (40 mg b.i.d.), and randomized to receive either curcumin (500 mg/day) or placebo as adjunct to standard treatment. Severity of dyspepsia symptoms was evaluated using the Hong Kong dyspepsia index (HKDI). Eradication of H. pylori infection was assessed using the urea breath test (UBT) at 4 weeks following the end of treatment. Results: Adjunctive therapy with curcumin was associated with a greater improvement of dyspepsia symptoms according to the HKDI score (change score: -12.90±2.81 vs. -9.60±3.39 in the curcumin and control group, respectively; p
    Original languageEnglish
    Pages (from-to)444-448
    Number of pages5
    JournalDrug Research
    Issue number8
    Publication statusPublished - 2016


    Dive into the research topics of 'Adjunctive Therapy with Curcumin for Peptic Ulcer: A Randomized Controlled Trial'. Together they form a unique fingerprint.

    Cite this